The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Long-acting beta2 agonists (salmeterol or formoterol) and combination products that contain salmeterol with fluticasone (Seretide Accuhaler) or formoterol with budesonide (Symbicort Turbohaler) are indicated for the management of chronic obstructive pulmonary disease (COPD). Although inhaled corticosteroids are not indicated for monotherapy in COPD, treatment guidelines (including those issued by the Global initiative on Obstructive Lung Disease, GOLD) 1 recommend that inhaled steroids may be added to ongoing bronchodilator therapy in COPD management.